# Retinoblastoma Phase II Expanded Access Clinical Trial

Source: https://onco.cc/trials/nct06679634/  
OnCo record `nct06679634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Topotecan in retinoblastoma, run by Targeted Therapy Technologies, LLC, now recruiting.

## Summary

Retinoblastoma Phase II Expanded Access Clinical Trial is a phase 2 interventional study registered as NCT06679634 by Targeted Therapy Technologies, LLC, with 30 participants planned, started 2025-02-21 and due to reach its primary completion in 2029-11. Interventions recorded: Chemoplaque also referred to as Episcleral Topotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06679634
- Phase: 2
- Setting: Retinoblastoma Phase II Expanded Access Clinical Trial
- Sponsor: Targeted Therapy Technologies, LLC
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06679634: https://clinicaltrials.gov/study/NCT06679634

## Connected records

- cancers: [Retinoblastoma](https://onco.cc/cancers/retinoblastoma/)
- drugs: [Topotecan](https://onco.cc/drugs/topotecan/)

---
JSON: https://onco.cc/api/v1/entities/nct06679634.json